Daewoong Pharma and Meheco International Expand Partnership for China’s Market Entry
Daewoong Pharma (KRX: 069620), a leading South Korean pharmaceutical company, has reportedly signed a memorandum...
Daewoong Pharmaceutical
Daewoong Pharmaceutical Files NDA in China for Potassium-Competitive Acid Blocker Fexuclu
South Korea-based Daewoong Pharmaceutical (KRX: 069620) has revealed that a new drug application (NDA) has...
Round 8 VBP Tender Results: RMB 3.775 Billion Awarded Across 152 Manufacturers
The official results of Round 8 of China’s national Volume-Based Procurement (VBP) tender program have...
Daewoong Pharmaceutical Licenses Bersiporocin to CSP for Greater China Development
South Korea-based Daewoong Pharmaceutical has entered into an exclusive licensing agreement with UK-based CS Pharmaceuticals...
HitGen Partners with Daewoong Pharmaceutical for Drug Discovery
China-based HitGen Inc. (SHA: 688222) has announced a research collaboration agreement with South Korea’s Daewoong...